WHAT HAPPENS TO A GLP-1 PRACTICE IF COMPOUNDED SEMAGLUTIDE GOES AWAY?The durability question, answered with the regulatory record and its actual dates — and the structural reason a practice's value should never sit inside a single molecule.

Educational overview · Approx. 11 min read · illustrative, not advice

The durability question, answered with the regulatory record and its actual dates — and the structural reason a practice's value should never sit inside a single molecule.

The third question, and the one that decides whether a model is real

After "what do I get" and "what does it cost," the question a capable buyer asks is: what happens to this business if compounded semaglutide is no longer available? It is the right question. A large share of the category's recent growth moved through compounding pharmacies during a specific, temporary regulatory condition. Anyone who waves that away is selling you a supply arbitrage and calling it a company.

So here is the record with dates attached, followed by the structural answer. Two ground rules first. We are not predicting what FDA will do — there is an open proceeding with a closed comment record and no announced outcome, and forecasting it would be dishonest. And nothing on this page is legal advice. Every item here is something to put in front of your own counsel, your own broker and your own pharmacy partner in your own market before you commit capital.

Why compounding scaled in the first place

Compounding sits under two federal pathways: 503A pharmacies compounding for an identified patient, and 503B outsourcing facilities compounding at larger scale. Both are constrained when a commercially available drug is not in shortage. When a drug is listed in shortage, those constraints loosen, and that is the window the compounded GLP-1 channel grew inside.

The window opened early. Wegovy was first listed in shortage in March 2022 and Ozempic in August 2022. During the shortage period, anti-obesity patients accounted for approximately 83% of the compounded GLP-1 market, according to IQVIA's October 2025 analysis. That is not a footnote. It means a very large commercial channel was built on a condition that was, by definition, temporary — shortages are declared, and shortages are resolved.

What ended, and exactly when

FDA removed tirzepatide from the shortage list in December 2024, with compounders expected to cease by March 2025. FDA declared the shortage of all doses of injectable semaglutide resolved on February 21, 2025. Enforcement discretion for 503A pharmacies ran to April 22, 2025, and for 503B outsourcing facilities to May 22, 2025.

Read that as an operator rather than as an observer. The permission structure underneath a very large number of businesses had a published expiry date, announced in advance, in writing. Any model whose core supply line carries a published expiry is a model with a clock inside it — and the clock was visible to anyone who read the notices. If you are evaluating a build that depends on that channel, the relevant question is not whether the operator survived 2025. It is what the operator changed.

The market did not stop, which is its own signal

IQVIA's October 2025 review found that compounded semaglutide and tirzepatide prescribing did not abate after delisting. More than 80% of compounded prescriptions include supplemental ingredients such as B vitamins or levocarnitine. And roughly 2% of compounded patients switched to branded products monthly.

Two honest readings. First, demand is sticky: patients who started on a compounded product largely did not migrate to branded product, even at the reported switching rate. Second, the channel adapted — a great deal of it moved toward formulations positioned as personalised rather than as copies of an approved drug. Sticky demand and an adaptive channel are real. Neither is evidence of durability. Those are separate claims, and only the first two are evidenced.

The live risk, with its dates on it

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound them from bulk substance. The comment period was extended, with comments due July 30, 2026.

One clause in that proposal deserves reading twice: FDA expressly rejected affordability and insurance access as constituting clinical need. Affordability is precisely the argument most of the compounded channel's consumer marketing rests on. It was addressed on the record and declined as a basis for clinical need. Separately, in September 2025 FDA issued more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide over statements the agency deemed false or misleading.

We will not tell you how this resolves, and you should distrust anyone who does. What we will tell you is that the proceeding exists, that it is docketed and public, and that it is the single most consequential open item for any business whose margin depends on compounded bulk supply. If a licensor has not raised it with you unprompted, that itself is diligence information.

What FDA says about the product itself

Set the supply question aside for a moment and look at the product-level statements, because they drive liability and reputation as much as regulation. FDA states that a compounded product may contain the same active ingredient but is not the drug FDA reviewed and approved, and that FDA does not evaluate specific compounded products for safety, effectiveness, manufacturing quality or consistency. The agency has received hundreds of adverse event reports associated with compounded semaglutide and tirzepatide, including reports linked to dosing errors, and has warned about fraudulently labelled product naming pharmacies that do not exist.

For a partner, that is not an abstraction. It is a question of who carries which policy, who is named on the label, and what your marketing says — which is exactly the ground covered in how insurance and liability get split between the two entities in a metabolic practice.

The price floor moved underneath the argument

The cost-advantage pitch has also been squeezed from the branded side. Manufacturer self-pay pricing through NovoCare Pharmacy starts at $149 per month for the 1.5 mg or 4 mg oral Wegovy doses for new patients, with the standard pen starting at $199 per month for the first two months as a limited-time offer and the HD 7.2 mg pen from $399 per month after the introductory period — all stated as subject to change and checked in August 2026.

Layer on the November 6, 2025 federal agreements: starting doses at $350 per month via the TrumpRx direct-to-consumer site that launched in January 2026, trending toward $245 per month over two years, a $245 Medicare price with a $50 monthly beneficiary copay, and roughly $150 per month for oral GLP-1s if approved. A business whose entire differentiation was "cheaper than branded" is now competing against a floor it does not set and cannot see moving until it has moved.

Cash-pay demand and compounded supply are not the same thing

Here is the distinction that most of this conversation misses. The compounded channel is a supply condition. Cash-pay demand is a coverage condition, and the two have different causes and different lifespans.

The coverage picture: Medicare Part D has been prohibited by statute from covering drugs used for weight loss since the program's creation under the 2003 Medicare Modernization Act. The temporary Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 at a $50 monthly copay, and those copays do not count toward Part D deductibles or out-of-pocket maximums. The BALANCE model began for Medicaid in May 2026 and was delayed indefinitely for Medicare Part D after plan participation fell short of an 80% enrollment threshold; state and plan participation are voluntary. On the employer side, coverage of GLP-1 agonists used primarily for weight loss reaches 16% of firms with 200–999 workers, 30% with 1,000–4,999, and 43% with 5,000 or more — with the largest-firm figure rising from 28% in 2024 to 43% in 2025, 59% of large covering firms reporting utilisation above projection and 66% reporting significant prescription drug spending impact.

The reasonable inference — and it is labelled an inference, not a finding — is that cash-pay demand in this category is produced by a statutory exclusion addressed only through temporary voluntary programs plus majority non-coverage among mid-sized employers, rather than by a temporary supply condition. That is a characterisation of the coverage landscape. It is not a demand forecast, and it says nothing whatsoever about what any operator will produce.

• US adult obesity prevalence was 40.3% and severe obesity 9.4% (August 2021–August 2023), with 46.4% prevalence among adults aged 40–59.
• 72.4% of US adults aged 20 and over had overweight including obesity over the same period.
• 18% of US adults say they have ever used a GLP-1 drug and 12% are currently using one, up six points in current use since May 2024.
• Among users, 56% reported difficulty affording the drug, 27% had insurance but paid the entire cost themselves, and 14% stopped because of cost.

The structural answer: own the relationship, not the molecule

Now the part that actually answers the question. A metabolic practice is only a single-molecule business if you build it as one. The failure mode is not regulatory — it is architectural. If enterprise value sits in a supply line, a docket entry can end it. If value sits in the member relationship, the program and the operating system around them, a supply change becomes a procurement event handled by the clinical side, not an existential one.

Atlas builds toward the second shape deliberately. Clinical decisions — including what is prescribed and from where — sit with a separately licensed medical entity. Atlas provides no medical services and employs no clinicians. What the license fee buys is the business layer: the program structure, the member-facing technology, the brand kit you own outright, the ordering and fulfilment workflow, and the operating playbooks. That is also why owning your brand outright changes what you are actually building, and why it is worth being precise about what 'turnkey' actually means when someone sells you a build.

• The member relationship and its renewal cadence — the thing a member re-enrols for is the program, not a vial.
• The program itself: intake, education, measurement, coaching, review points, and what happens in month nine.
• The brand and the list — owned by the partner, portable across any supply change.
• Operating discipline: how a market is worked, how enquiries are handled, how retention is measured week over week.

What to verify before you sign anything

Take this list to any licensor in this category, including us. The answers are more informative than the brochures, and a licensor who cannot answer them in writing has told you something.

• Ask, in writing, what happens to the build if a specific molecule becomes unavailable — and what changes operationally in the following 30 days.
• Ask what proportion of the program's structure is molecule-specific versus molecule-agnostic.
• Ask who holds the pharmacy relationship, whether the partner can replace it, and what happens to the member if it changes.
• Ask to see the consumer marketing claims and who reviewed them — the September 2025 warning letters were about statements, not chemistry.
• Ask what is licensed to you permanently versus what you lose access to if the relationship ends. The diligence questions worth asking before licensing anything cover the rest.
• Then take all of it to your own counsel. Nothing here is a substitute for that, and no licensor's compliance posture transfers to your entity.

If the answer holds up, the next step is a fit call

Atlas does not publish the license fee, and that is deliberate rather than coy: the number belongs in a conversation where the market, the entity structure and the clinical relationship are all on the table at once. Where the figure goes, we write The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. — one-time, 0% of revenue, no ongoing partner fees.

Atlas takes a limited number of partner builds at a time (Ask Atlas to put this in writing: partner slots per quarter), because a build consumes real delivery capacity and a market deserves a partner who can actually work it. The application is a qualification step in both directions. If the durability answer above is the one you were looking for, start the application — and if the fit call says no, that is a legitimate outcome and we will say it plainly.

FREQUENTLY ASKED QUESTIONS.